Literature DB >> 22197901

Cytokines and Behcet's disease.

Z Y Zhou1, S L Chen, N Shen, Y Lu.   

Abstract

Behcet's Disease (BD) is a systemic vasculitis of unknown etiology. Increasing studies find that a sophisticated interlacing cytokine network is closely implicated in the onset, evolution and even organ damages of the disease. Cytokines involved can be categorized as Th1 type, Th2 type, Th17 type, chemokines and other proinflammatory cytokines, etc. The vicious cycle of cytokine network plays a substantial role in the disease pathogenesis and even in organ lesions, and might be disorganized by blocking one of the key links of the cytokines, which in turn may provide essential clues to outlook the target therapy regimen of cytokine agents in BD. There have been a number of case reports of the positive efficacies of cytokine (and cytokine blocker) agents including Infiximab (Human murine chimeric Anti-TNF α monoclonal antibody), Anakinra (recombinant, non-glycosylated human IL1 receptor antagonist) etc in BD. IFN-α had been used clinically in treating BD with uveitis with beneficial efficacy ever since the 1980s. The studies to date suggested that IL6, IP10 are involved in BD with nervous system lesions, IL17, IL18 are relevant to the superimposed uveitis in patients with BD. Some cytokines i.e. IL8, RANTES, MIP-1α are associated with the disease activity, whereas others are exemplified by that of IL10, whose level shows negative relevance to the disease activity, might be potentially cytokine of protecting effect. According to the related genetic study, the SNPs of numerous cytokines including IL1, TNFα, IFNγ, IL12, and IL18 are pertinent to BD. The recent GWAS (Genome Wide Association Studies) demonstrated that SNPs in the IL10 and IL23R-IL12RB2 region are associated with the disease. Most studies nowadays are confined within the cytokines in the peripheral blood levels, owing to the potentially significant roles of certain cytokines in local lesions. It warrants further in-depth study to address this issue. Moreover, it deserves multi-centre study considering the unique geographical "silk road" display picture of the disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197901     DOI: 10.1016/j.autrev.2011.12.005

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  50 in total

Review 1.  The genomic landscape of human immune-mediated diseases.

Authors:  Xin Wu; Haiyan Chen; Huji Xu
Journal:  J Hum Genet       Date:  2015-08-20       Impact factor: 3.172

2.  Low prevalence of obesity in Behçet's disease is associated with high obestatin level.

Authors:  Süleyman Serdar Koca; Murat Kara; Metin Özgen; Ramazan Dayanan; Caner Feyzi Demir; Kader Aksoy; Nevin İlhan; Emir Dönder; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2017-06-01

3.  PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.

Authors:  Luca Cantarini; Antonio Vitale; Giulia Bersani; Laura Martin Nieves; Marco Cattalini; Giuseppe Lopalco; Francesco Caso; Luisa Costa; Florenzo Iannone; Giovanni Lapadula; Mauro Galeazzi; Angela Ceribelli; Enrico Brunetta; Carlo Selmi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2015-02-10       Impact factor: 2.980

Review 4.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

5.  Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease.

Authors:  Abdullah Kursat Cingu; Fatih Mehmet Turkcu; Serdar Aktas; Alparslan Sahin; Orhan Ayyildiz
Journal:  Int Ophthalmol       Date:  2020-07-29       Impact factor: 2.031

6.  Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease.

Authors:  Suleyman Serdar Koca; Murat Kara; Firat Deniz; Metin Ozgen; Caner Feyzi Demir; Nevin Ilhan; Ahmet Isik
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

Review 7.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 8.  Behçet's syndrome pathophysiology and potential therapeutic targets.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Mario Milco D'Elios; Lucia Ciucciarelli; Domenico Prisco; Lorenzo Emmi
Journal:  Intern Emerg Med       Date:  2014-01-12       Impact factor: 3.397

Review 9.  Behcet's disease with peripheral nervous system involvement successfully treated with golimumab: a case report and review of the literature.

Authors:  Menghui Yao; Congcong Gao; Chunyi Zhang; Xueqi Di; Wenfang Liang; Wenbo Sun; Qianqian Wang; Zhaohui Zheng
Journal:  Rheumatol Int       Date:  2020-07-16       Impact factor: 2.631

10.  [Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome].

Authors:  L X Sun; J J Liu; Y X Hou; C R Li; L Li; X P Tian; X F Zeng; W J Zheng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.